Category Archives: Cell Therapy

Stem Cell Therapy to Treat Equine Tendon Injuries A brief explanation of tendon injuries and how stem cell therapy can be used to treat them. By: Animal Science … Continue reading →

Stem Cell Therapy: Dr. Roberta Shapiro - A NY Physician's Path to Panama Special Guest Speaker, Roberta F. Shapiro DO, FAAPM R speaks about: A New York Doctor's Path to Panama at the Stem Cell Institute's Stem Cell Therapy Publi... By: http://www.cellmedicine.com … Continue reading →

Buddy the beagle can walk again Buddy the beagle wasn't able to walk when he first arrived at the University of Minnesota Veterinary Medical Center. With the help of U of M veterinarians and staff, using stem-cell therapy,... By: UMN Veterinary Medical Center … Continue reading →

Vista, Ca, (PRWEB) November 23, 2014 DC Labs, nationwide provider of the luxurious Ovation Cell Therapy, introduces new retail opportunity to their Salon Professional Division. Previously, the Ovation Hair product line was available exclusively online. Ovation Hair launched their Salon Professional Division in 2013, to offer training and certification to licensed stylists interested in learning about the benefits of Cell Therapy as well as offer In-Salon treatments to their clients. The program was received with huge success and has grown exponentially since its inception. Lead Stylist, Brenda Stearns explains, As Certified Cell Therapists, we have been requesting this retail opportunity with Ovation since we began offering In-Salon Cell Therapy Treatments. Based on years of salon experience, we were certain clients would want to walk out of the salon product in hand - once we introduced the amazing benefits of thicker, stronger, longer hair to them. Ms. Stearns continues, This is truly a fabulous opportunity for us as stylists as well as for our clientele. Ovation Hair is releasing the entire line of hair care products to salons currently offering Cell Therapy Treatments. The complete Ovation hair care line includes shampoos, conditioners and styling products that address individual hair care needs … Continue reading →

Federico Mingozzi: "Translational research in the in vivo gene therapy of monogenic diseases" Educational Day* at ESGCT Conference in Madrid. Federico Mingozzi - Head of Immunology and Liver Gene Transfer at Gnthon in Paris - talks on "Translational research in the in vivo gene... By: European Society for Gene and Cell Therapy … Continue reading →

PUBLIC RELEASE DATE: 21-Nov-2014 Contact: Quinn Eastman qeastma@emory.edu 404-727-7829 Emory Health Sciences @emoryhealthsci Patients who receive more cells get significant benefits. That's a key lesson emerging from a clinical trial that was reported this week at the American Heart Association meeting in Chicago. In this study, doctors treated heart attack patients with their own bone marrow cells, selected for their healing potential and then reinjected into the heart, in an effort to improve the heart's recovery. In the PreSERVE-AMI phase II trial, physicians from 60 sites treated 161 patients, making the study one of the largest to assess cell therapy for heart attacks in the United States. The study was sponsored by NeoStem, Inc. "This was an enormous undertaking, one that broke new ground in terms of assessing cell therapy rigorously," says the study's principal investigator, Arshed Quyyumi, MD, professor of medicine at Emory University School of Medicine and co-director of the Emory Clinical Cardiovascular Research Institute. "We made some real progress in determining the cell type and doses that can benefit patients, in a group for whom the risks of progression to heart failure are high." All participating patients received the standard of care -- stent placement -- and … Continue reading →

Kilian Before After Stemlogix Stem Cell Therapy dog with arthritis treated with autologous stem cells. By: mark Greenberg … Continue reading →

Damian Garcia Olmo: "Clinical trials with mesenchymal stromal cells in wound healing" Educational Day* at ESGCT Conference in Madrid. Prof. Damin Garca Olmo: "Clinical trials with mesenchymal stromal cells in wound healing" http://iccam.es/prof-damian-garcia-olmo/ By: European Society for Gene and Cell Therapy … Continue reading →

By: Adam Feuerstein | 11/18/14 - 10:16 AM EST Inject a cocktail of undifferentiated stem cellsinto a patient who has suffered a heart attack, and days or even weekslater, the stem cells transform into cardiac cells and rebuild the damaged heart muscle. Months later, the patient has a "new" healthy heart.It's a great story. But so far, the proof remains elusive though not for a lack of trying. The latest company to fulfill this ambitious scenario is NeoStem (NBS) which presented disappointing (but not surprising) results from a small study of its proprietary cardiac stem-cell therapy NBS10 at the American Heart Association annual meeting Monday. NeoStem tried to put some positive spin on the bad news but shares are down 25% to $5.10. NBS10, formerly known as AMR-001, is an autologous stem-cell therapy derived from a patient's own bone marrow. When injected back into patients following a heart attack, the stem cells are supposed torestore blood flow, rebuild damaged cardiac muscle and improve function. Except in NeoStem's study, NBS10 fell short on two primary endpoints designed to assess the therapy's efficacy. The study used non-invasive imaging to assess blood flow through the heart, six months after a single infusion of … Continue reading →

Published 18 November 2014 Kite Pharma, a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, has announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending KTE-C19 for designation as an orphan medicinal product for the treatment of diffuse large B cell lymphoma (DLBCL). KTE-C19 is an anti-CD19 CAR T cell therapy that involves genetically modifying a patient's T cells to express a CAR that is designed to target CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias. The COMP, a committee of the EMA, adopts an opinion on the granting of orphan drug designation, after which the opinion is submitted to the European Commission for endorsement of the opinion. Orphan drug designation by the European Commission provides regulatory and financial incentives for companies to develop and market therapies that treat a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the European Union (EU), and where no satisfactory treatment is available. In addition to a 10-year period of marketing exclusivity in the EU after product approval, orphan drug designation provides … Continue reading →